Osiris Therapeutics

Osiris Therapeutics, Inc. The company was founded in March 1993 following the identification of MSCs by Dr. Arnold Caplan and colleagues at Case Western Reserve University in Cleveland Ohio. Dr. Caplan contributed a license to the technology and joined Kevin Kimberlin and Peter Friedli to launch Osiris.[1]

Osiris Therapeutics
IndustryPharmaceuticals
Headquarters
Columbia, Maryland
,
United States
Key people
Dwayne Montgomery
(CEO)
Greg Law
(CFO)
Frank Czworka
(COO)
Alla Danilkovitch
(CSO)
ProductsGrafix, Cartiform, BIO4,
Websiteosiris.com

Osiris received the first regulatory clearance in the world for a systemically administered stem cell drug,[2] called Prochymal or remestemcel-L.[3] In 2013, Osiris sold its MSC drug and patents to Mesoblast of Australia and the drug was renamed Ryoncil.[4]

By 2018, MSCs were being studied in more than 1,000 clinical trials[5] to treat 928 different medical conditions.

Ryoncil was tested in a March 2020 pilot study at Mount Sinai Hospital in New York City on late-stage, ventilator-assisted Covid-19 patients suffering Acute Respiratory Distress Syndrome.[6] Based on the results, the FDA approved a Phase 2/3 study on 300 patients at 30 sites around the U.S. The Cardiothoracic Surgical Trials Network, funded by the NIH, and Mesoblast (the owner of the product) commenced that trail on May 5, 2020.[7]

References
  1. Vertes, Alain, Quershi, Nasib, Caplan, Arnold. I. Stem Cells in Regenerative Medicine, John Wiley & Sons, 2015. Pg. 676
  2. Osiris Therapeutics, Inc. Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, for the Fiscal Year Ended December 31, 2012, UNITED STATES SECURITIES AND EXCHANGE COMMISSION
  3. "Prochymal - First Stem Cell Drug Approved". www.medicalnewstoday.com. 2012-05-22. Retrieved 2020-08-13.
  4. Waltz, Emily (2013-12-01). "Mesoblast acquires Osiris' stem cell business". Nature Biotechnology. 31 (12): 1061–1061. doi:10.1038/nbt1213-1061. ISSN 1546-1696.
  5. S.Kusakawa, R.Sawada,.YasudaT.,KurodaY.Sato, “Trends in global clinical trial registration for MSC-based therapeutic products”, Cytotherapy, Volume 22, Issue 5, Supplement, May 2020, Page 165. Elsevier Inc.
  6. Sheikh, Knvul; Thomas, Katie (2020-04-08). "More Coronavirus Vaccines and Treatments Move Toward Human Trials". The New York Times. ISSN 0362-4331. Retrieved 2020-08-13.
  7. Knapp, Alex. "Clinical Trials Of Mesoblast's Stem Cell Treatment For COVID-19 Set To Begin Soon". Forbes. Retrieved 2020-08-13.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.